Replenishable prevascularized cell encapsulation devices increase graft survival and function in the subcutaneous space.
Replenishable prevascularized cell encapsulation devices increase graft survival and function in the subcutaneous space.
复制标题
DOI：
10.1002/btm2.10520
复制
发表时间：
2023-07
影响因子：
7.4
通讯作者：
中科院分区：
文献类型：
--
作者：
1型糖尿病（T1D）患者的β细胞替代疗法（BCRT）通过补充被自身免疫攻击破坏的内源性β细胞来改善血糖调节。包括免疫隔离在内的一些限制使这种疗法无法充分发挥其潜力。用于BCRT的细胞封装装置为产生胰岛素的β细胞提供保护性物理屏障，从而保护移植细胞免受免疫攻击。然而，移植后装置植入不良导致营养剥夺和缺氧，对移植的β细胞造成代谢应激。移植部位包封装置的预血管化有助于在植入物周围建立宿主血管网络，增加溶质向被包封细胞的运输。在这里，我们提出了一种可补充的预血管植入方法（RPVIM），该方法允许血管整合可补充的封装装置在皮下空间。空包封装置血管化14天，之后在不破坏周围血管的情况下插入产生胰岛素的细胞。将RPVIM装置与非预血管化装置（标准植入方法[SIM]）和先前建立的预血管化装置（标准预血管化植入方法[SPVIM]）进行比较。结果表明，超过75%的含有干细胞来源的胰岛素生成β细胞簇的RPVIM装置在皮下植入28天后显示出信号。值得注意的是，不仅RPVIM装置显示信号的百分比明显高于SIM和SPVIM装置，而且腹腔内葡萄糖耐量试验和组织学分析表明，包被干细胞衍生的胰岛素产生β细胞群在RPVIM装置中保留了其功能，这对T1D的成功治疗至关重要。
Beta cell replacement therapy (BCRT) for patients with type 1 diabetes (T1D) improves blood glucose regulation by replenishing the endogenous beta cells destroyed by autoimmune attack. Several limitations, including immune isolation, prevent this therapy from reaching its full potential. Cell encapsulation devices used for BCRT provide a protective physical barrier for insulin‐producing beta cells, thereby protecting transplanted cells from immune attack. However, poor device engraftment posttransplantation leads to nutrient deprivation and hypoxia, causing metabolic strain on transplanted beta cells. Prevascularization of encapsulation devices at the transplantation site can help establish a host vascular network around the implant, increasing solute transport to the encapsulated cells. Here, we present a replenishable prevascularized implantation methodology (RPVIM) that allows for the vascular integration of replenishable encapsulation devices in the subcutaneous space. Empty encapsulation devices were vascularized for 14 days, after which insulin‐producing cells were inserted without disrupting the surrounding vasculature. The RPVIM devices were compared with nonprevascularized devices (Standard Implantation Methodology [SIM]) and previously established prevascularized devices (Standard Prevascularization Implantation Methodology [SPVIM]). Results show that over 75% of RPVIM devices containing stem cell‐derived insulin‐producing beta cell clusters showed a signal after 28 days of implantation in subcutaneous space. Notably, not only was the percent of RPVIM devices showing signal significantly greater than SIM and SPVIM devices, but the intraperitoneal glucose tolerance tests and histological analyses showed that encapsulated stem‐cell derived insulin‐producing beta cell clusters retained their function in the RPVIM devices, which is crucial for the successful management of T1D.
登录
查看更多内容
DOI：
10.1007/s10856-018-6178-6
发表时间：
2018-11-09
期刊：
Journal of materials science. Materials in medicine
影响因子：
--
作者：
Groot Nibbelink M;Skrzypek K;Karbaat L;Both S;Plass J;Klomphaar B;van Lente J;Henke S;Karperien M;Stamatialis D;van Apeldoorn A
通讯作者：
van Apeldoorn A
DOI：
10.1002/smll.202104899
发表时间：
2022-03
期刊：
Small (Weinheim an der Bergstrasse, Germany)
影响因子：
--
作者：
Liu W;Flanders JA;Wang LH;Liu Q;Bowers DT;Wang K;Chiu A;Wang X;Ernst AU;Shariati K;Caserto JS;Parker B;Gao D;Plesser MD;Grunnet LG;Rescan C;Pimentel Carletto R;Winkel L;Melero-Martin JM;Ma M
通讯作者：
Ma M
DOI：
10.1073/pnas.1708806115
发表时间：
2018-01-09
影响因子：
11.1
作者：
An, Duo;Chiu, Alan;Ma, Minglin
通讯作者：
Ma, Minglin
影响因子：
23.9
作者：
Kharbikar, Bhushan N.;Mohindra, Priya;Desai, Tejal A.
通讯作者：
Desai, Tejal A.
影响因子：
8.2
作者：
Magisson, Jordan;Sassi, Aladin;Sigrist, Severine
通讯作者：
Sigrist, Severine